Lixisenatide for the treatment of type 2 diabetes

Drugs of Today

Volumn 49, Issue 9, 2013, Pages 537-553

  Petersen, A B ^a   Knop, F K ^a   Christensen, Mikkel ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Efficacy; Exendin 4 analogue; GLP 1; GLP 1R agonist; Incretin mimetic; Lixisenatide; Tolerability; Type 2 diabetes

Indexed keywords

ATORVASTATIN; DIGOXIN; ETHINYLESTRADIOL; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HEMOGLOBIN A1C; INSULIN GLARGINE; LEVONORGESTREL; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PARACETAMOL; RAMIPRIL; SULFONYLUREA; WARFARIN;

ADD ON THERAPY; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIBODY PRODUCTION; AREA UNDER THE CURVE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BODY MASS; CARCINOGENICITY; CREATININE CLEARANCE; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; EVENING DOSAGE; GLOMERULUS FILTRATION; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART PALPITATION; HEART RATE; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN RELEASE; INSULIN SYNTHESIS; KIDNEY TUBULE ABSORPTION; LETHARGY; LIPOTOXICITY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREATITIS; POSTPRANDIAL STATE; PROTEIN METABOLISM; RECEPTOR BINDING; REFLEX; REPRODUCTIVE TOXICITY; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; STOMACH EMPTYING; TACHYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; URTICARIA; VOMITING;

EID: 84885198025     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.09.2020940     Document Type: Review

References (48)

1. Holst, J.J. The physiology of glucagon-like peptide 1. Physiol Rev 2007, 87(4): 1409-39. (Pubitemid 350041474)
2. Nauck, M.A., Heimesaat, M.M., Behle, K. et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002, 87(3): 1239-46. (Pubitemid 36121094)
3. Larsson, H., Holst, J.J., Ahrén, B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 1997, 160(4): 413-22. (Pubitemid 27342031)
4. Abu-Hamdah, R., Rabiee, A., Meneilly, G.S., Shannon, R.P., Andersen, D.K., Elahi, D. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 2009, 94(6): 1843-52.
5. Trapp, S., Hisadome, K. Glucagon-like peptide 1 and the brain: central actions-central sources? Auton Neurosci Basic Clin 2011, 161(1-2): 14-9.
6. Shyangdan, D.S., Royle, P., Clar, C., Sharma, P., Waugh, N., Snaith, A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev Online 2011, (10): CD006423.
7. Vilsbøll, T., Christensen, M., Junker, A.E., Knop, F.K., Gluud, L.L. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012, 344: d7771.
8. Madsbad, S., Kielgast, U., Asmar, M., Deacon, C.F., Torekov, S.S., Holst, J.J. An overview of once-weekly glucagon-like peptide-1 receptor agonists - available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 2011, 13(5): 394-407.
9. Christensen, M., Knop, F.K., Holst, J.J., Vilsboll, T. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs 2009, 12(8): 503-13.
10. Werner, U., Haschke, G., Herling, A.W., Kramer, W. Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept 2010, 164(2-3): 58-64.
11. Thorkildsen, C., Neve, S., Larsen, B.D., Meier, E., Petersen, J.S. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther 2003, 307(2): 490-6. (Pubitemid 37310661)
12. European Medicines Agency. European Public Assessment Reports - Lyxumia [Internet]. 2013 [cited June 18, 2013]. Retrieved from: Available from: http://www.ema.europa.eu.
13. nd Annu Meet Eur Assoc Study Diabetes (EASD) (September 14-17, Copenhagen) 2006; (September 14-17, Malmö) 2006, Abst 0659.
14. th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 6-10, San Francisco) 2008, Abst 11-OR.
15. Tews, D., Werner, U., Eckel, J. Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues. Horm Metab Res 2008, 40(3): 172-80. (Pubitemid 351690520)
16. st Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 24-28, San Diego) 2011, Abst 0968-P.
17. nd Annu Meet Eur Assoc Study Diabetes (EASD) (September 14-17, Copenhagen) 2006; (September 14-17, Malmö) 2006, Abst 0656.
18. th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 22-26, Chicago) 2007, Abst 486-P.
19. rd Annu Meet Eur Assoc Study Diabetes (EASD) (September 17-21, Amsterdam) 2007, Abst 0584.
20. Frank, T. Population pharmacokinetics of lixisenatide, a once-daily human glucagon-like peptide-1 receptor agonist, in healthy subjects and in patients with type 2 diabetes. J Pharm Drug Deliv Res 2013, 02(01).
21. European Medicines Agency. Summary of product characteristics - Lyxumia [Internet]. http://www.ema.europa.eu. Accessed June 18, 2013.
22. European Medicines Agency. European Public Assessment Reports - Byetta [Internet]. http://www.ema.europa.eu. Accessed November 5, 2010.
23. Bjerre Knudsen, L., Madsen, L.W., Andersen, S. et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010, 151(4): 1473-86.
24. Seino, Y., Min, K.W., Niemoeller, E., Takami, A.; EFC10887 GETGOAL-L Asia Study Investigators. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 2012, 14(10): 910-7.
25. Fonseca, V.A., Alvarado-Ruiz, R., Raccah, D. et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 2012, 35(6): 1225-31.
26. th Sci Meet Asian Assoc Study Diabetes (November 24-27, Kyoto) 2012, Abst PCS: 20-3.
27. Bolli, G., Munteanu, M., Dotsenko, S., Niemoeller, E., Wardȩcki M, Hanefeld, M. Long-term tolerance (up to 2 years) of lixisenatide once daily vs. placebo in patients with type 2 diabetes not adequately balanced with metformin (GetGoal-F1). Diabet Metab 2012, 38(Suppl. 2): p324.
28. Horowitz, M., Rayner, C.K., Jones, K.L. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes. Adv Ther 2013, 30(2): 81-101.
29. th Scientific Meeting of the Asian Association for the Study of Diabetes, Kyoto, 2012, Abst PCS-30-5.
30. Riddle, M.C., Forst, T., Aronson, R. et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care 2013, 36(9): 2497-503.
31. Riddle, M.C., Aronson, R., Home, P. et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013, 36(9): 2489-96.
32. Rosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., Gerich, J.E. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care 2013, Epub ahead of print.
33. Kapitza, C., Forst, T., Coester, H.-V., Poitiers, F., Ruus, P., Hincelin-Méry, A. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab 2013, 15(7): 642-9.
34. Ahrén, B., Leguizamo Dimas, A., Miossec, P., Saubadu, S., Aronson, R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care 2013, 36(9): 2543-50.
35. Pinget, M., Goldenberg, R., Niemoeller, E., Muehlen-Bartmer, I., Guo, H., Aronson, R. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab 2013, Advance publication.
36. th Annu Meet Eur Assoc Study Diabetes (EASD) (September 12-16, Lisbon) 2011, Abst 785.
37. De Heer, J., Holst, J.J. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes 2007, 56(2): 438-43.
38. rd Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 21-25, Chicago) 2013, Abst 916-P.
39. Cohen, D. FDA is to assess data linking type 2 diabetes drugs with pancreatitis. BMJ 2013, 346: f1808.
40. Ratner, R.E., Rosenstock, J., Boka, G. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med 2010, 27(9): 1024-32.
41. Makris, K., Spanou, L. Is there a relationship between mean blood glucose and glycated hemoglobin? J Diabetes Sci Technol 2011, 5(6): 1572-83.
42. rd Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 21-25, Chicago) 2013, Abst 1038-P.
43. rd Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 21-25, Chicago) 2013, Abst 1047-P.
44. th Annu Meet Eur Assoc Study Diabetes (EASD) (October 1-5, Berlin) 2012, Abst 815.
45. Lorenz, M., Pfeiffer, C., Steinsträßer, A. et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes - relationship to postprandial glycemia. Regul Pept 2013, 185C: 1-8.
46. th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 6-10, San Francisco) 2008] 2008, 57(Suppl. 1): Abst 520-P.
47. th Annu Meet Eur Assoc Study Diabetes (EASD) (October 1-5, Berlin) 2012, Abst 814.
48. th Annu Meet Eur Assoc Study Diabetes (EASD) (September 12-16, Lisbon) 2011, Abst 784.